When can checkpoint inhibitors be used to treat urothelial carcinoma?
Phase III METEOR trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma
Balancing the benefits and costs of immunotherapy in the treatment of lung cancer
Patient care must be considered when using new anticancer drugs